BEAT - BioTelemetry, Inc.
| Previous Close | 40.80 |
| Open | 40.90 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 1000 |
| Day's Range | 40.25 - 41.35 |
| 52 Week Range | 23.30 - 42.36 |
| Volume | 207,476 |
| Avg. Volume | 395,172 |
| Market Cap | 1.343B |
| Beta | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.53 |
| Earnings Date | May 1, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.60 |
- Market Realist•15 hours ago
Analyzing BEAT, SUPN, ADBE And RHT Stocks
BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market cap had gained 373% between 2013 and 2017.
- Market Realist•16 hours ago
Total Returns and Sector Exposure for Growth Indexes—Continued
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.
Yahoo Finance•13 days agoAmerica's top fund is run by a father-son duo from the shores of Lake Minnetonka
The best performing mutual fund so far this year - beating the S&P 500 by more than 20% - is run by a small-town duo of father and son.
- GlobeNewswire•25 days ago
Consolidated Research: 2018 Summary Expectations for AdvanSix, Flagstar, CalAmp, Agree Realty, Cowen Group, and BioTelemetry — Fundamental Analysis, Key Performance Indications
NEW YORK, April 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Thomson Reuters StreetEvents•26 days ago
Edited Transcript of BEAT earnings conference call or presentation 25-Apr-18 9:00pm GMT
Q1 2018 BioTelemetry Inc Earnings Call
- Associated Press•26 days ago
BioTelemetry: 1Q Earnings Snapshot
On a per-share basis, the Malvern, Pennsylvania-based company said it had net income of 17 cents. Earnings, adjusted for one-time gains and costs, came to 39 cents per share. The results beat Wall Street ...
- GlobeNewswire•27 days ago
BioTelemetry, Inc. Reports First Quarter 2018 Financial Results
MALVERN, Pa., April 25, 2018-- BioTelemetry, Inc., the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of ...
- GlobeNewswire•last month
BioTelemetry, Inc. to Release First Quarter 2018 Earnings Results on April 25, 2018
MALVERN, Pa., April 19, 2018-- BioTelemetry, Inc. will release its first quarter 2018 earnings on Wednesday, April 25 at 4:00 PM Eastern Time.. The BioTelemetry quarterly conference call will be held at ...
American City Business Journals•last monthHealthcare and biotech investor Sami Hamade dies
Hamade had spent the past three-plus years as a partner with New York-based Apple Tree Partners.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of BEAT earnings conference call or presentation 22-Feb-18 10:00pm GMT
Q4 2017 BioTelemetry Inc Earnings Call
- GlobeNewswire•2 months ago
BioTelemetry, Inc. (Nasdaq: BEAT) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its 10th Listing Anniversary
What: BioTelemetry, Inc. will visit the Nasdaq MarketSite in Times Square in celebration of its 10th listing anniversary. BioTelemetry, Inc. is the leading wireless medical technology company focused on ...
Market Realist•2 months agoWhat Analysts Recommend for Amedisys and Peers in March 2018
Amedisys (AMED) is a healthcare services company with a focus on providing home care through three segments: home health, hospice, and personal care. Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating. Two analysts have given the stock a “buy” rating, while six analysts have given it a “hold” rating.
Market Realist•3 months agoA Look at BioTelemetry’s Financial Performance
Here's What's in Store for BioTelemetry in 2018
Market Realist•3 months agoUnderstanding BioTelemetry’s Business Strategy
BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services, expand in the research market, and leverage its monitoring platform in new markets. In order to increase the demand for its portfolio of outpatient cardiac monitoring solutions, BioTelemetry is focusing on educating cardiologists, electrophysiologists, and neurologists on the benefits of using mobile cardiac telemetry for arrhythmia monitoring while stressing the increased diagnostic yield and ability to deliver more effective treatments.
Market Realist•3 months agoAnalyst Ratings for BioTelemetry and Its Peers in March 2018
BioTelemetry (BEAT) provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. In July 2017, BioTelemetry acquired LifeWatch, a supplier of mobile cardiac monitoring solutions. The acquisition is expected to help BioTelemetry create a comprehensive connected healthcare platform and deliver solutions in the market more effectively.
Market Realist•3 months agoExploring BioTelemetry’s Segments
BioTelemetry (BEAT) operates in three segments: healthcare, research, and technology. The healthcare segment contributed 81% of BioTelemetry’s total revenues in fiscal 2017. Under this segment, BioTelemetry offers a full spectrum of solutions with a single source of cardiac monitoring services to cardiologists, electrophysiologists, neurologists, and primary care physicians.
- Zacks•3 months ago
BioTelemetry (BEAT) Beats Q4 Earnings and Revenue Estimates
BioTelemetry (BEAT) sees strong Q4 results, courtesy of solid acquisitions and promising performance by the MCT platform.
- GlobeNewswire•3 months ago
Analysis: Positioning to Benefit within Bluerock Residential Growth REIT, National Presto Industries, Healthways, Deluxe, BioTelemetry, and Modine Manufacturing — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- ACCESSWIRE•3 months ago
Free Research Report as LabCorp's Revenue Jumped 13.2%; Adjusted EPS Advanced 14%
Stock Monitor: BioTelemetry Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 1, 2018 / Active-Investors.com has just released a free earnings report on Laboratory Corp. of America Holdings (NYSE: ...
- ACCESSWIRE•3 months ago
Blog Exposure - PerkinElmer to Takeover Australian Biotech Company RHS Ltd
Stock Monitor: BioTelemetry Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 28, 2018 / Active-Investors.com has just released a free research report on PerkinElmer, Inc. (NYSE: PKI ). If you ...
- GuruFocus.com•3 months ago
BioTelemetry Inc (BEAT) Files 10-K for the Fiscal Year Ended on December 31, 2017
BioTelemetry Inc (NASDAQ:BEAT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
- Associated Press•3 months ago
BioTelemetry reports 4Q loss
The Malvern, Pennsylvania-based company said it had a loss of 48 cents per share. Earnings, adjusted for non-recurring costs, came to 32 cents per share. The results exceeded Wall Street expectations. ...
- GlobeNewswire•3 months ago
BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results
Company Delivers Record Revenue and Adjusted EBITDA Exceeds Expectations. MALVERN, Pa., Feb. 22, 2018-- BioTelemetry, Inc., the leading mobile and wireless medical technology company focused on the delivery ...
- Benzinga•3 months ago
BioTelemetry Q4 Earnings Preview
On Thursday, BioTelemetry (NASDAQ: BEAT ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Based on BioTelemetry management projections, analysts ...
